Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
Publishing timestamp: 2025-03-29 15:02:07
Summary
Novo Nordisk's diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, lowering the risk of cardiovascular-related death, heart attack, and stroke by 14% compared to a placebo. This paves the way for Rybelsus to become a new treatment option for people with diabetes and established heart disease.
Sentiment: POSITIVE
Keywords: pharmaceuticals, lilly drn, business news, biotechnology, novo nordisk a/s, health care industry, biotech and pharmaceuticals, science, business, breaking news: business,